Dr. Ronald Lehman is first in NYC to Perform PROlat™ Procedure with Mazor Robotics Technology
PROlat is a single-position solution for placing pedicle screws and other spinal hardware in the lateral decubitus position
“The PROlat™ solution by Mazor Robotics will transform the way antepsoas and lateral spine surgery is performed,” said Dr. Lehman, nationally acclaimed orthopaedic surgeon. “Technology has never been able to save me time in the OR, but during my first case with PROlat, we saved over an hour of time without having to flip the patient. It was a seamless and easy integration.”
Dr. Lehman also documented that only seven (7) seconds of fluoroscopy was used during the procedure – a significant reduction compared to what would have been used with standard fluoroscopy or navigation (which requires an intraoperative CT scan) – and, in turn, lowered radiation exposure for surgeon and staff.
“Dr. Lehman is a Professor of Orthopaedic Surgery with tenure, the Chief of Degenerative, Minimally Invasive and Robotic Spine Surgery, and a leading national and international spine surgeon. His adoption of the Renaissance system continues to validate the clinical value proposition of our technology,” said Ori Hadomi, Mazor Robotics CEO.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the benefits of the PROlat solution, and other statements containing the words believes, anticipates, plans, expects, will and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor's annual report on Form 20-F filed with the SEC on May 2, 2016 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.
MAZOR Robotics UG. / Location Germany
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.
Press releases you might also be interested in
Weitere Informationen zum Thema "Medizintechnik":
Smart Cities knacken 2025 weltweit die 2-Billionen-Dollar-Marke
Das Marktforschungsunternehmen Frost & Sullivan prognostiziert für die Smart City goldene Zeiten. Im Jahr 2025 soll sie Geschäftsmöglichkeiten im Wert von zwei Billionen US-Dollar generieren. In der Hauptrolle der Smart Cities: Künstliche Intelligenz.Weiterlesen